• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

New Research Funding Opportunity??


Senior Member
Received this today. I don't know what this really means though. Anyone with grant experience here?

-----Original Message-----
From: NIH ME/CFS Research Working Group [mailto:NIH_MECFS_WG-L@LIST.NIH.GOV] On Behalf Of Susan Maier
Sent: Monday, July 23, 2012 3:14 PM
Subject: Funding Opportunity Announcement

Institutional Clinical and Translational Science Award (U54)

The purpose of the Institutional Clinical and Translational Science Awards (CTSA) is to strengthen the entire spectrum of NIH supported translational research. Through integrated homes that build upon and support institutional scientific strengths, they provide research resources and workforce training that improve the quality, validity, generalizability, and efficiency of clinical and translational research. These awards are the centerpiece of the NCATS CTSA program.


CTSAs are made to degree granting institutions or groups of institutions that receive significant funding from the NIH. CTSAs require institutional commitment, the status of a major scientific and administrative entity within and across an applicant and partner institution(s), and a CTSA PD(s)/PI(s) with the authority and influence necessary to successfully create an institutional home for clinical and translational research. This may include authority, perhaps shared with other high level institutional officials, over requisite space, resources, faculty appointments, protected time, and promotions.

Institutional CTSAs support an academic home that creates an integrated research and training environment across an applicant institution and its partner institutions in order to:

Promote an institutional environment that enhances quality, safety, efficiency, and cost effectiveness of clinical and translational research for all conditions;
Provide resources and services to support and speed the planning and implementation of clinical and translational research across the entire range of research and communities;

Facilitate the training and career development of a robust translational research workforce.

Institutional CTSAs are encouraged to develop programs tailored to meet the needs of their own investigative and public communities and to develop and build upon unique institutional and community strengths. All sites are expected to provide core resources for the entire spectrum of translational research; however, focused programs may be developed to meet the needs of local investigators and build on unique institutional strengths. Possible examples of such programs include, but are not limited to, the following:

Resources for early stage translational research, e.g., high through-put screening, medicinal chemistry, pre-clinical toxicology, target validation; Clinical pharmacology units for ‘first in man’ studies; Extensive investment in human physiological phenotyping; Biomarker and clinical assessment validation; Multi-site collaboration, including expertise in global health; Practical trials in health care settings; Programs developing innovative models for patient and community engagement in research.